Brighter reaffirms the communicated market vision for Actiste

Report this content

Due to questions raised by a group of shareholders regarding the configuration of the incentive program (LTI) proposed in the notice of Brighters' Annual General Meeting, the Board of Directors of Brighter wishes to reaffirm the market vision for the diabetes service Actiste, announced in 2018. The goal is to achieve a 30 percent market share within five years from market entry. The performance targets of the incentive program, in the form of certain sales, EBITDA and share price development, are based on the company developing in line with this target vision, although the vision itself does not constitute one of the defined performance targets. The estimated potential is based on the assessment that the service satisfies a great unmet need amongst users as well as healthcare providers, authorities and community actors, and that it can be offered at a competitive price.

The company also wishes to emphasize that implementation of the proposed LTI program is strategically important in order to achieve the company's ambitious goals. The structure is completely cash flow neutral and based on creating long-term value for the company's shareholders. Not implementing the LTI program would likely have a negative impact on the company's recently launched commercial activities and would result in an increased need for additional capital raising. Additionally, the company's attractiveness as an employer would be weakened in an important shift where the organization is being built up for expansion and commercial activity, working towards reaching the market vision.

For further information, please contact:

Certified Adviser
Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10,,

About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award.

The Company's shares are listed on Nasdaq First North Growth Market/BRIG.


Documents & Links